文献速递淋巴瘤造血干细胞移植与细胞治疗

CD22靶向CAR-T细胞疗法使CD19 CAR难治性大B细胞淋巴瘤获完全缓解

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.
PubMed 文献 · Blood · 2021-01-01

该研究报道了首3例自体CD19 CAR-T治疗难治的大B细胞淋巴瘤患者,接受单次输注1×10^6/kg CAR22 T细胞的I期剂量递增试验。CAR22耐受性较好,无>2级非血液学不良事件;3例均获完全缓解,末次随访(平均7.8个月,范围6–9.3)时均持续缓解,CAR22细胞扩增峰值85.4–350个/微升,>3个月仍可检测。

要点

  • CD19 CAR-T难治性LBCL患者接受单次CAR22输注后3例均达完全缓解。
  • 未观察到>2级非血液学不良事件,耐受性较好。
  • CAR22细胞扩增峰值85.4–350个/微升,>3个月仍持续存在。

核心结论

  • CD22靶向CAR-T可使CD19 CAR-T难治性大B细胞淋巴瘤患者获得完全缓解且耐受性较好。

研究设计与样本

  • I期剂量递增研究,报道首3例连续的自体CD19 CAR-T难治性LBCL患者。
  • 单次输注自体1×10^6/kg CAR+ T细胞靶向CD22。

主要发现

  • 3例患者均达到完全缓解,末次随访时所有缓解持续(平均7.8个月,范围6–9.3)。
  • 未观察到高于2级的非血液学不良事件。
  • 循环CAR22细胞扩增峰值范围85.4–350个/微升,所有患者>3个月仍可检测。
  • 输注后>6个月影像学持续缓解且循环肿瘤DNA相应下降。

关键数值与推荐

  • CAR22单次输注剂量为1×10^6 CAR+ T细胞/kg。
  • CAR22细胞扩增峰值范围85.4–350个/微升。
  • 末次随访平均7.8个月(范围6–9.3),所有缓解持续。

临床怎么用

  • 对于CD19 CAR-T治疗后进展的LBCL患者,可考虑CD22靶向CAR-T作为后续治疗选择。
  • 治疗期间需监测CAR22细胞扩增及循环肿瘤DNA变化以评估疗效。

局限性

  • 仅报道首3例患者,样本量小。
  • 为I期剂量递增研究,更高剂量水平仍在入组中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion of autologous 1 × 106 CAR+ T cells per kilogram targeting CD22 (CAR22) as part of a phase 1 dose-escalation study. CAR22 therapy was relatively well tolerated, without any observed nonhematologic adverse events higher than grade 2. After infusion, all 3 patients achieved complete remission, with all responses continuing at the time of last follow-up (mean, 7.8 months; range, 6-9.3). Circulating CAR22 cells demonstrated robust expansion (peak range, 85.4-350 cells per microliter), and persisted beyond 3 months in all patients with continued radiographic responses and corresponding decreases in circulating tumor DNA beyond 6 months after infusion. Further accrual at a higher dose level in this phase 1 dose-escalation study is ongoing and will explore the role of this therapy in patients in whom prior CAR T-cell therapies have failed. This trial is registered on clinicaltrials.gov as #NCT04088890.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Baird JH, Frank MJ, Craig J, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2021. PMID: 33512414. doi:10.1182/blood.2020009432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。